

FOR MORE INFORMATION GO TO
[HTTPS://PROFESSIONAL.HEART.ORG/EN/MEETINGS/SCIENTIFIC-SESSIONS](https://professional.heart.org/en/meetings/scientific-sessions)

AGENDA

Introduction

Gregg Fonarow, MD (Chair)

A New Era of Personalized Treatment of HFrEF

Gregg Fonarow, MD

Improving Contractility and Outcomes in
Patients with HFrEF

Scott Solomon, MD

Omecamtiv Mecarbil for HFrEF Management:

Additional Insights


John Teerlink, MD

Case Presentation: "Current and Emerging Treatment
Options for the Patient with Worsening HF"

Jane Wilcox, MD, MSc



CHAIR



Gregg Fonarow, MD

Interim Chief, UCLA Division of Cardiology
Eliot Corday Chair in Cardiovascular Medicine and Science
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

FACULTY



Scott Solomon, MD

The Edward D. Frohlich Distinguished Chair
Professor of Medicine
Harvard Medical School
Boston, Massachusetts



John Teerlink, MD

Professor of Medicine
University of California, San Francisco School of Medicine
Director of Heart Failure
San Francisco Veterans Affairs Medical Center
San Francisco, California



Jane Wilcox, MD, MSc

Associate Professor of Medicine
Northwestern University Feinberg School of Medicine
Chicago, Illinois



Voxmedia LLC
1 Bethany Road, Bldg. 3, Suite 48
Hazlet, NJ 07730



SCAN THIS CODE
TO REGISTER

Managing the Heart Failure
Patient with Reduced
Ejection Fraction:

New Perspectives and
Emerging Evidence

FOR MORE INFORMATION GO TO
[HTTPS://PROFESSIONAL.HEART.ORG/EN/MEETINGS/SCIENTIFIC-SESSIONS](https://professional.heart.org/en/meetings/scientific-sessions)

PAID ADVERTISEMENT


FOR MORE INFORMATION GO TO
[HTTPS://PROFESSIONAL.HEART.ORG/EN/MEETINGS/SCIENTIFIC-SESSIONS](https://professional.heart.org/en/meetings/scientific-sessions)

JOIN US FOR A VIRTUAL CME SATELLITE EVENT
AT THE AHA SCIENTIFIC SESSIONS 2021



Managing the Heart Failure
Patient with Reduced
Ejection Fraction:

New Perspectives and
Emerging Evidence



Saturday, November 13, 2021

5:30 PM – 7:00 PM (Eastern Time)

AND ON-DEMAND

Chair

Gregg Fonarow, MD

Faculty

Scott Solomon, MD

John Teerlink, MD

Jane Wilcox, MD, MSc

This event is not part of the official Scientific Sessions 2021 as planned by
the AHA Committee on Scientific Sessions Programming.

This program is
sponsored by



This activity is supported by an independent
educational grant from Cytokinetics Incorporated.



SCAN THIS CODE
TO REGISTER

REGISTER ONLINE AT:
<https://professional.heart.org/en/meetings/scientific-sessions>



PROGRAM OVERVIEW

A central factor in the pathogenesis of heart failure (HF) with reduced ejection fraction (HFrEF) is the initial decrease in systolic function. Pharmacological agents that improve myocardial performance can be categorized based on 3 myocardial mechanisms: calcitropes, which alter intracellular calcium concentrations; myotropes, which affect the molecular motor and scaffolding; and mitotropes, which influence energetics. Omecamtiv mecarbil, an investigational therapy which improves contraction by a novel mechanism of action, has demonstrated a reduction in the risk of a composite of a first heart failure event or cardiovascular death, with an excellent safety and tolerability profile.

New therapies are becoming available for the treatment of HFrEF, providing the clinician with more opportunities for an individualized approach to pharmacotherapy. Patients with worsening HF are particularly challenging; guideline-directed medical therapy (GDMT) often cannot be optimized in these patients due to a variety of factors (such as multiple organ system involvement, lower glomerular filtration rate, higher risk of hyperkalemia, lower systolic blood pressure, and higher risk of medication side effects/intolerance). There is an unmet need for new therapies to improve ventricular performance and clinical outcomes in this difficult-to-treat patient population. In this program, HF experts will provide insights into mechanisms for improving myocardial contractility and clinical evidence and emphasize the need for a more personalized treatment of HFrEF. A case discussion will illustrate current best practices for patients with worsening HF, and identify a potential role for emerging therapies.

TARGET AUDIENCE

This educational activity is intended for clinicians who manage patients with heart failure (HF).

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants should be able to:

- Categorize pharmacologic agents that improve myocardial contractility based on distinct myocardial mechanisms
- Interpret analyses from a clinical outcomes trial with omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (HFrEF)
- Discuss the treatment of patients with worsening HF

EDUCATIONAL GRANT

Voxmedia International gratefully acknowledges the educational grant provided by Cytokinetics Incorporated.

ACCREDITATION AND CREDIT DESIGNATION STATEMENT



Voxmedia LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Voxmedia LLC designates this activity for a maximum of *1.5 AMA PRA Category Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts *AMA PRA Category 1.5 Credits*[™] through its reciprocity agreements.

The National Commission on Certification of Physician Assistants accepts *AMA PRA Category 1 Credits*[™] from organizations accredited by the ACCME.

DISCLOSURE INFORMATION

Voxmedia strives to ensure fair-balance, independence, objectivity, and scientific rigor in all directly or jointly sponsored educational activities. All prospective faculty are required to disclose to Voxmedia all financial relationships for the preceding 24 months (1) with any commercial interest producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients AND (2) with any commercial supporters prior to participating in the planning of an activity or developing content. Only after Voxmedia mitigates all financial relationships may faculty receive approval to participate, and are expected to contribute evidence-based material. Faculty are required to indicate areas of their presentation that are based on professional opinion vs. guidelines, meta-analysis. All information submitted will be peer-reviewed. The intent of this disclosure is not to prevent faculty from participating, but rather to provide learners with information on which they can make their own judgment of commercial bias. Voxmedia will disclose to learners that all relevant financial relationships have been mitigated in either written materials, visually and/or verbally. It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation. Speakers must make a meaningful disclosure to the audience of their discussions of any unlabeled or investigational use(s) of drugs or devices.

AMERICANS WITH DISABILITIES ACT



Voxmedia fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant of this activity is in need of accommodation, please call and/or submit in writing to: Voxmedia, 1 Bethany Rd. Bldg 3, Suite 48, Hazlet, NJ 07730. Phone: 973-467-0500.

**JOIN US FOR A VIRTUAL CME SATELLITE EVENT
AT THE AHA SCIENTIFIC SESSIONS 2021**

Managing the Heart Failure Patient with Reduced Ejection Fraction:

**New Perspectives and
Emerging Evidence**

**AND ON-DEMAND
at AHA Scientific Sessions 2021**

Saturday, November 13, 2021

5:30 PM – 7:00 PM (Eastern Time)

Chair

Gregg Fonarow, MD

Faculty

Scott Solomon, MD

John Teerlink, MD

Jane Wilcox, MD, MSc

